

Asthma – Allergy Workgroup Recommendations, May 2006

The Workgroup recommends the Pharmacy and Therapeutics Committee consider the following for the drug classes in this category:

Inhaled Anticholinergics

Remove prior authorization from Combivent®

Antihistamines-2<sup>nd</sup> Generation

Remove prior authorization from generic fexofenadine

Beta Adrenergics-Short Acting

Add prior authorization requirement to Maxair Autohaler®

Beta Adrenergics-Long Acting

No changes to current designations

Beta Adrenergics for Nebulizers

Add prior authorization requirement for metaproterenol

Beta Adrenergic/ Corticosteroid Combinations

No change to current designations

Inhaled Systemic Corticoids

Add Flovent HFA® to list without prior authorization

Leukotriene Inhibitors

No change to current designations

Nasal Steroids

Remove Nasalide®

Remove prior authorization from Nasacort AQ®

Add generic fluticasone propionate without prior authorization